Pasi Janne, MD, Oncology, Boston, MA, Brigham and Women's Hospital

PasiAnteroJanneMD

Oncology Boston, MA

Hematologic Oncology

Associate Professor of Medicine, Dana-Farber Cancer Institute

Dr. Janne is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Janne's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Hematology/Oncology, 1998 - 2001
  • Brigham and Women's Hospital
    Brigham and Women's HospitalInternship, Internal Medicine, 1996 - 1997
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1996

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1998 - 2022
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Elected Member The American Society for Clinical Investigation, 2008

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
    The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung CancerMarch 3rd, 2020
  • KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung
    KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the LungJanuary 30th, 2020
  • Revisiting Chemo in EGFR-Mutant NSCLC
    Revisiting Chemo in EGFR-Mutant NSCLCDecember 3rd, 2019
  • Join now to see all

Grant Support

  • The Use Of Whole-Exome Sequencing To Guide The Care Of Cancer PatientsNational Human Genome Research Institute2012
  • EML4-ALK: A Potential Therapeutic Target In Lung CancerNational Cancer Institute2009–2012
  • Drug Resistance In Lung CancerNational Cancer Institute2008–2011
  • Mechanisms Of Acquired Resistance To Egfr-Targeted AgentsNational Cancer Institute2008–2009

Professional Memberships

Hospital Affiliations